Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

Article English OPEN
Benjamin Arthurs, MD; Kathy Wunderle, MD; Maylee Hsu, MD; Suil Kim, MD, PhD;
  • Publisher: Elsevier
  • Journal: Respiratory Medicine Case Reports,volume 21,pages27-29 (issn: 2213-0071, eissn: 2213-0071)
  • Related identifiers: pmc: PMC5369366, doi: 10.1016/j.rmcr.2017.03.011
  • Subject: Ibrutinib | Invasive aspergillosis | Chronic lymphocytic leukemia | BAL, Bronchoalveolar lavage | BTK, Bruton's tyrosine kinase | Diseases of the respiratory system | Case Report | TLR, Toll-like receptor | RC705-779 | Aspergillus | Bruton's tyrosine kinase | CLL, Chronic lymphocytic leukemia

We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses a... View more
Share - Bookmark